ArticleCureus2025
Proteinase 3-Antineutrophil Cytoplasmic Antibody (PR3-ANCA)-Associated Vasculitis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of rare, heterogeneous, and potentially life-threatening diseases, typically characterized by their phenotype (microscopic polyangiitis, granulomatosis with polyangiitis, or eosinophilic granulomatosis with polyangiitis) but currently classified according to the type of antibody that is identified: proteinase 3 (PR3), myeloperoxidase (MPO), or negative. A 55-year-old man presented with a two-week history of fever, myalgias, and odynophagia, and two days of pleuritic pain, cough, hemoptysis, and purpuric lesions on both inferior limbs. CT scan documented multiple lung nodules surrounded by ground-glass opacities, and laboratory tests showed increased erythrocyte sedimentation rate, acute kidney injury, microscopic hematuria, and non-nephrotic proteinuria. Additional tests revealed PR3-ANCA positivity. Diffuse alveolar hemorrhage was confirmed, and a kidney biopsy unveiled pauci-immune focal crescentic glomerulonephritis. After two weeks of glucocorticoids, he initiated rituximab, with a gradual, promising response. Effective treatment is vital in chronic inflammatory diseases, such as AAV, with an impact on both organ damage and global prognosis, which is why this diagnosis should be considered in the presence of suspected clinical signs or symptoms, to achieve better therapeutic results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.